Eric Assenat

7PUBLICATIONS
51CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jul 24, 2026
Prognostic Impact of Concomitant Genomic Alterations in FGFR2-Positive Cholangiocarcinoma Treated With Pemigatinib.

|Jun 21, 2025
Regorafenib plus modified gemcitabine-oxaliplatin in patients with advanced biliary tract cancer. The randomized phase Ib/II BREGO study.

Jean-Frédéric Blanc, Mohamed Bouattour, Ludovic Gauthier

|Jun 20, 2025
Impact of Lean Body Mass-Based Oxaliplatin Dose Calculation on Neurotoxicity in Adjuvant Treatment of Stage III Colon Cancer: Results of the Phase II Randomized LEANOX Trial.

Eric Assenat, Meher Ben Abdelghani, Sophie Gourgou

|Apr 04, 2025
Neoadjuvant FOLF(IRIN)OX Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Multicenter Randomized Noncomparative Phase II Trial (PANACHE01 FRENCH08 PRODIGE48 study).

Lilian Schwarz, Jean-Baptiste Bachet, Aurelia Meurisse

|Jan 06, 2021
Phase II study evaluating the association of gemcitabine, trastuzumab and erlotinib as first-line treatment in patients with metastatic pancreatic adenocarcinoma (GATE 1).

Eric Assenat, Laurent Mineur, Caroline Mollevi

|May 01, 2019
Idarubicin-loaded Beads for Chemoembolization of Hepatocellular Carcinoma: The IDASPHERE II Single-Arm Phase II Trial.

Boris Guiu, Patrick Chevallier, Eric Assenat

Pageof 2

Frequent Collaborators

2 joint publications

Mohamed Bouattour

2 joint publications

Pierre Senesse

2 joint publications

Thibault Mazard

2 joint publications

Anthony Turpin